Another new Chinese medicine approved, will grab more than 1 billion drug market

In recent years, with the country's strong support for the development of Chinese medicine, the Chinese medicine industry has entered a period of vigorous development
.
At the same time, Chinese medicine companies have also ushered in rare development opportunities
.
In this context, in order to seize development opportunities, Chinese medicine companies have begun to strengthen the research and development of Chinese medicine products; affected by this, more and more new Chinese medicine drugs have gradually emerged in the industry
.
Recently, Yangtze River Pharmaceutical Group Jiangsu Longfengtang’s new Chinese medicine Class 1.
1 Qingchang Wenzhong Tablet was approved for clinical use.
This new drug is an intestinal drug.
This is the second new Chinese medicine approved for clinical use in Yangtze River this year.
The approved indication It is used to treat ulcerative colitis with mixed cold and heat, damp-heat and stasis syndrome
.
Data shows that in the physical pharmacies of cities in China, the market size of Chinese patent medicines for enteric medicine is more than 1 billion yuan.
The impact of the epidemic will decline slightly in 2020, but it is expected to exceed 1.
5 billion yuan in 2021
.
The author was informed that in fact, in addition to the Qingchang Wenzhong tablet of Jiangsu Longfengtang of Yangtze River Pharmaceutical Group, many new Chinese medicines have also been approved this year
.
For example, on November 25, the CDE website showed that Jiangxi Qingfeng Pharmaceutical Co.
, Ltd.
's application for registration of salvianolic acid A for injection of a new Chinese medicine of category 1.
2 was accepted
.
This is the 54th new Chinese medicine registration application accepted by CDE this year
.
On November 10, the website of the State Food and Drug Administration showed that it had recently approved the registration application of Kangyuan Pharmaceutical Yinqiao Qingre Tablets.
This new Chinese medicine was launched on the market, providing a new treatment option for patients with common colds
.
It is worth mentioning that Yinqiao Qingre Tablet is the sixth new Chinese medicine approved for marketing this year, and it is also the first Chinese medicine of category 1.
1 approved for marketing since the implementation of the new Chinese medicine registration classification on July 1, 2020
.
In addition, from January to October this year, two new Chinese medicine applications by Tasly and Yiling Pharmaceutical, and one new Chinese medicine application by Kangyuan Pharmaceutical and Jingxin Pharmaceutical have also been accepted by CDE
.
On the whole, compared with the whole year of 2020, the number of new Chinese medicine registration applications has increased by more than 80% so far this year, and the number of new Chinese medicine registration applications has reached a record high
.
In addition to the record high number, the distribution of new Chinese medicines is also very rich in the field of treatment, mainly focusing on drugs for digestive system, respiratory system and cardiovascular and cerebrovascular diseases, with 9, 8, and 5 drug registration applications respectively
.
The analysis believes that in the past few years, the number of new Chinese medicines approved for marketing is small.
The reason is that the new Chinese medicine review system that meets the characteristics of Chinese medicine needs to be improved.
Therefore, the industry has a wait-and-see attitude towards the research and development of new Chinese medicines, and its enthusiasm has always been Needs to be improved
.
However, in order to solve key problems such as the obvious lack of innovation and research and development power of traditional Chinese medicine in recent years, and to better promote the development of the traditional Chinese medicine industry, in recent years, the state has issued a series of policy documents to guide the work of traditional Chinese medicine, and clearly made the creation of new traditional Chinese medicines into traditional Chinese medicine.
One of the key tasks of development
.
Among them, in particular, the National Medical Products Administration's "Implementation Opinions on Promoting the Inheritance, Innovation and Development of Traditional Chinese Medicines" issued by the National Medical Products Administration at the end of 2020 put forward higher standards and requirements for the development of new Chinese medicines, and at the same time, it also provides a boost for the research and development of new Chinese medicines.
Here comes a new historical development opportunity
.
In general, with the support of favorable national policies, Chinese medicine companies are accelerating the research and development of new drugs, and the number of innovative Chinese medicines is also expanding rapidly
.
However, it should be noted that the industry predicts that as more new Chinese medicines are launched in the future, it may not only challenge the market position of traditional exclusive varieties, but may also bring a new round of reshuffle of Chinese medicine companies
.